Allogeneic hematopoietic transplantation is an effective therapy for a range of malignancies. High doses of myelosuppressive chemotherapy or radiation have been used in preparative regimens with the goal of preventing graft rejection and eradicating malignancy. Much of the benefit of transplantation, however, results from graft-versus-malignancy effects, mediated by donor immunocompetent cells. An alternative approach is to utilize less toxic, nonmyeloablative preparative regimens to achieve engraftment and allow graft-versusmalignancy effects to develop. This strategy reduces the risk of treatment-related mortality and allows transplantation for elderly or medically infirm patients not eligible for myeloablative therapy. Nonmyeloablative preparative regimens appear promising in diagnoses sensitive to graft-versus-malignancy effects and provide a platform for further development of cellular immunotherapy. Controlled clinical trials are warranted to define the role of nonmyeloablative allogeneic transplants in a range of hematologic malignancies and selected solid tumors. Bone Marrow Transplantation (2001) 27, Suppl. 2, S13-S22. Keywords: nonmyeloablative allogeneic transplantation; graft-versus-malignancy effect Allogeneic hematopoietic stem cell transplantation is an effective therapy for a range of hematologic, immune metabolic, and neoplastic diseases. High doses of myelosuppressive chemotherapy or radiation have been used in this therapy as an immunosuppressive preparative regimen to prevent graft rejection. Hematopoietic transplants have been extensively utilized as a treatment for malignancy. Many malignancies exhibit a steep dose-response relationship to chemo-or radiotherapy, with higher doses producing greater cytoreduction. Hematopoietic transplantation allows escalation of doses of many agents beyond those producing severe bone marrow toxicity. The allogeneic marrow transplant was initially considered a supportive care modality to restore hematopoiesis after 'curative' supralethal myeloablative chemotherapy and/or radiation.
Allogeneic hematopoietic stem cell transplantation is an effective therapy for a range of hematologic, immune metabolic, and neoplastic diseases. High doses of myelosuppressive chemotherapy or radiation have been used in this therapy as an immunosuppressive preparative regimen to prevent graft rejection. Hematopoietic transplants have been extensively utilized as a treatment for malignancy. Many malignancies exhibit a steep dose-response relationship to chemo-or radiotherapy, with higher doses producing greater cytoreduction. Hematopoietic transplantation allows escalation of doses of many agents beyond those producing severe bone marrow toxicity. The allogeneic marrow transplant was initially considered a supportive care modality to restore hematopoiesis after 'curative' supralethal myeloablative chemotherapy and/or radiation. has become clear, however, that the high-dose therapy does not eradicate the malignancy in many patients, and that the therapeutic benefit of allogeneic marrow transplantation is largely related to an associated immune-mediated graftversus-malignancy effect. This realization has led to the development of less toxic transplant regimens using nonmyeloablative preparative regimens to achieve engraftment and allow development of graft-versus-malignancy effects as a primary form of therapy.
Graft-versus-malignancy and donor lymphocyte infusions
Extensive clinical and experimental data support the presence of the graft-versus-malignancy effect (Table 1) . Most studies relate to the treatment of hematologic malignancies, graft-versus-leukemia, or graft-versus-lymphoma (GVL) effects. There is a reduced risk of leukemia relapse in patients with acute and chronic graft-versus-host disease (GVHD). [2] [3] [4] There is a higher risk of relapse after syngeneic bone marrow transplantation [5] [6] [7] and after T cell-depleted allotransplants. 8, 9 These data indicate that minimal residual disease is present in many patients post-transplant, which can lead to relapse if GVL is not present.
The most direct evidence supporting the concept of GVL is the observation that patients who relapse after allogeneic transplantation may be reinduced into complete remission by infusing additional donor lymphocytes. [10] [11] [12] [13] [14] Following engraftment of an allogeneic hematopoietic transplant, immune reconstitution generally occurs exclusively from donor-derived immunocompetent cells. In patients who Table 1 Clinical evidence supporting an allogeneic graft-versusmalignancy effect In patients relapsing after allogeneic hematopoietic transplantation, the malignancy typically recurs in host cells, but residual immunity remains donor-derived. Therefore, donor lymphocyte infusions (DLI) are not rejected, but GVHD and GVL effects may develop. Most data relate to the treatment of chronic myelogenous leukemia (CML) recurring into a chronic phase after allogeneic transplantation. After donor lymphocyte infusion, antileukemic effectors proliferate and presumably must reach a critical threshold level at which time host-derived leukemia and normal hematopoietic cells are rapidly eradicated, 15 followed by recovery from donor-derived normal hematopoietic cells. 10, 16, 17 Marrow aplasia may occur unless sufficient donor-derived normal progenitors are present to restore hematopoiesis. 18 Consistent with this premise, CML patients with advanced relapse in which hematopoiesis is largely leukemic in origin are more likely to develop marrow aplasia than patients in early relapse in which donor-derived hematopoietic cells predominate.
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Mechanism of graft-versus-malignancy effects
Clinically, malignancy-specific reactivity can only rarely be demonstrated after allogeneic hematopoietic transplantation. Donor-derived T cell clones from allogeneic chimeras typically react against both host-derived normal hematopoietic cells and the leukemia, [19] [20] [21] and both populations are usually eliminated in responsive patients. 22 Graft-versus-malignancy responses may occur coincident with GVHD. However, many patients achieve a GVL response (ie leukemia remission) without developing GVHD. Although this is consistent with the premise that different target antigens may be involved with each process, responses could result from greater sensitivity of malignant cells than visceral tissues to a common immunologic mechanism. Graft-versus-leukemia/lymphoma activity could be due to reactivity against hematopoietic lineage-related antigens or malignancy-specific targets. Minor histocompatibility antigens restricted to the hematopoietic lineage have been described. [23] [24] [25] [26] [27] [28] Over-or abnormally expressed cellular constituents could also serve as target antigens for GVL. Proteinase-3, a serine protease present in myeloid primary granules, is overexpressed in CML and some cases of acute myelogenous leukemia (AML); it may serve as a target for an antileukemic immune response. Peptide antigens derived from proteinase-3 can stimulate generation of autologous or allogeneic T cell cytotoxicity against leukemia. [29] [30] [31] Other candidate overexpressed genes include myeloperoxidase and WT1. 32 Thus, graft-versus-malignancy could involve broad reactivity overlapping with GVHD, or restricted antihematopoietic or disease-specific responses. The potential target antigens for graft-versus-solid tumor effects are unknown, but overexpressed tissue antigens or polymorphic tissue-restricted antigens could be involved. It is also possible that GVHD could produce antitumor effects through cytokines or mechanisms other than specific T cell cytotoxicity.
Effector cells of graft-versus-malignancy
The effector cells involved with GVHD and GVL are incompletely defined. Both CD4 + and CD8 + T-cells participate in the pathophysiology of GVHD; natural killer cells, macrophages, and other cell populations are subsequently recruited and cytokines participate as mediators of tissue injury. [33] [34] [35] [36] [37] In animal models of graft-versus-leukemia, both CD4 + and CD8 + effectors have been described. In most systems, CD8
+ cells appear to be the primary effector cells of GVL. [38] [39] [40] In human BMT recipients, both CD4 + and CD8
+ cytotoxic antileukemic T cell clones have been described. 19, 41 In patients transplanted for CML, several recent studies have identified CD4 + T cell lines or clones that either inhibit the growth of leukemia progenitors or are directly lytic. 21, [42] [43] [44] Natural killer cells have also been implicated as GVL effectors.
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Considerations for nonmyeloablative preparative regimens for induction of graft-versus-malignancy
High-dose myeloablative therapy with allogeneic hematopoietic transplantation carries a high risk of treatmentrelated complications ranging from 10% to Ͼ50% depending on histocompatibility, disease and patient factors. Because the risks increase with advancing age, allotransplants are generally reserved for young patients without comorbidities. Recently, nonmyeloablative preparative regimens with reduced toxicity have been developed that are sufficiently immunosuppressive to prevent graft rejection. Since some malignancies are potentially cured by graft-versus-malignancy effects alone, (ie DLI), an alternative therapeutic strategy is to utilize a nonmyeloablative preparative regimen to achieve engraftment, and induce graft-versus-malignancy as the primary therapy. In nonmalignant disorders, it may not be necessary to ablate diseased tissues, but only to achieve mixed chimerism to provide a source of normal hematopoietic cells.
As a working definition, a truly nonmyeloablative regimen should allow relatively prompt hematopoietic recovery (Ͻ28 days) without a transplant and, upon engraftment, mixed chimerism should occur. Conversely, an ablative regimen requires hematopoietic transplantation for recovery and complete chimerism occurs upon engraftment. Nonablative preparative regimens do not eradicate recipient immunity and depend on the activity of donor T cells to achieve engraftment. The intensity of immunosuppression required for engraftment depends on the immunocompetence of the recipient, histocompatibility, and the composition of the transplant. Initial studies focused on patients with an HLA-matched sibling. More intensive regimens are required for engraftment in settings of greater genetic disparity including unrelated donor or HLA nonidentical transplants.
We and others have evaluated this nonmyeloablative transplant strategy. [48] [49] [50] [51] [52] The general treatment scheme is illustrated in Figure 1 . The nonablative preparative regimen does not completely eliminate host-derived cells; allogeneic donor-derived T cells induce a graft-versus-hematopoiesis effect, in which donor cells eradicate residual host hematopoiesis with reconstitution by donor cells, as well as graftversus-malignancy effects. This process takes months to complete.
Nonablative regimens have been studied as a means to reduce regimen-related toxicity in patients considered ineligible for myeloablative preparative regimens due to advanced age or comorbidities. Nonablative regimens may also reduce the risk of severe acute GVHD, since the clinical manifestations of acute GVHD partly result from the toxicity of the preparative regimen and subsequent cytokine release, as well as graft alloreactivity. 53, 54 Residual host T cells may also suppress GVHD. Infectious complications may also be reduced. Neutropenia is reduced or eliminated. In addition, the nonablative preparative regimen does not immediately eliminate host-derived immunocompetent cells, which can provide limited host defense early posttransplant.
There are also potential disadvantages of using nonablative preparative regimens. Higher doses of busulfan or total body radiation have been shown to reduce the risk of relapse in CML 55 and AML. 56 Approximately one-third of patients with good-risk leukemias are cured with high-dose therapy and syngeneic transplants in which GVL effects would not be expected to occur. 5, 6, 8 Young patients without Bone Marrow Transplantation comorbidities tolerate supralethal regimens well, and reducing toxicity may not improve their survival. Reliance on the antimalignancy effects of alloreactive T cells may increase morbidity due to chronic GVHD.
Disease susceptibility to graft-versus-malignancy effects
There are major differences among malignancies in their susceptibility to GVL effects, and hence their sensitivity to nonmyeloablative allogeneic transplants (Table 2) . CML is the disease in which GVL effects are best documented. T cell-depleted transplants are associated with a five-fold increase in the risk of relapse. 8, 9, 57, 58 Minimal residual disease can be detected early post-transplant in the majority of patients with CML using polymerase chain reaction-based techniques. [59] [60] [61] [62] [63] Malignant cells become undetectable after 6 months post-transplant in most patients receiving unmodified (T cell-replete) marrow transplants, presumably due to GVL effects. Greater than 70% of CML patients relapsing into a chronic phase achieve complete remission with donor lymphocyte infusions. 10, 12, 16, 64, 65 In responders, residual leukemia becomes undetectable by polymerase chain reaction analysis for bcr-abl rearrangement, and these responses are generally durable.
Indolent lymphoid malignancies also appear very sensitive to graft-versus-malignancy effects. Allogeneic transplants are associated with a substantially lower relapse rate than purged autologous transplants. [66] [67] [68] Selected patients with chronic lymphocytic leukemia (CLL) or low-grade lymphoma have responded to donor lymphocyte infusions 69 or modification of immunosuppressive therapy. [70] [71] [72] [73] [74] These data have led to trials of nonablative allogeneic transplants; in preliminary studies, many patients with low-grade lymphoma, mantle cell lymphoma, or CLL have achieved durable remissions. 50, 75, 76 A common characteristic of malignancies highly sensitive to GVL is that the malignant cells are derived from Table 2 Sensitivity to graft-versus-malignancy effects 5, 6 but the relapse rate is only minimally affected by T cell depletion. 8, 78 Approximately one-third of AML or myelodysplasia patients respond to donor lymphocyte infusions, but unlike the case in CML, these remissions are generally transient. 10, 16, 79, 80 Similarly, approximately one-third of patients with multiple myeloma also have transient responses to donor lymphocyte infusions. 81, 82 There is relatively little data to assess the responsiveness of Hodgkin's disease to GVL effects. Relatively few allogeneic transplants have been done, usually in patients with far advanced disease. There has been a high rate of treatment-related mortality and analyses to date have not detected a graft-versus-malignancy effect. 68, 83 Recently, however, pilot studies have described complete responses to nonablative transplants in Hodgkin's disease patients resistant to chemotherapy. 84, 85 Acute lymphoblastic leukemia and high-grade lymphoma appear relatively insensitive to GVL effects, 6, 8, 9 although patients with GVHD do have a reduced risk of relapse. The malignant lymphoblasts typically lack co-stimulatory molecules and do not effectively stimulate an immune response. 86, 87 The rapid rate of proliferation of these malignancies may also outpace a developing immune response. Only rare patients with these diagnoses have responded to donor lymphocyte infusions.
Graft-versus-tumor effects may also occur against solid tumors, although few studies with allogeneic transplantation have been performed. Pilot studies in breast cancer have reported antitumor responses in patients with graftversus-host disease, suggesting a graft-versus-adenocarcinoma effect. 88, 89 Major antitumor responses have been reported in renal cell carcinoma, usually concomitant with the development of acute GVHD. 22, 90 Further studies are required to determine whether graft-versus-tumor effects will be sufficiently active to justify the added morbidity related to allogeneic transplantation.
Nonablative preparative regimens
Most nonablative preparative regimens have utilized purine analogs, alkylating agents, or low-dose total body radiation.
91-100 Purine analogs (fludarabine or cladribine) have activity against a wide range of hematologic malignancies and are sufficiently immunosuppressive in standard doses to allow engraftment of HLA-compatible hematopoietic progenitor cells.
Giralt et al 91 initially evaluated use of standard-dose purine analog-based chemotherapy as a nonablative preparative regimen in patients with advanced myeloid leukemia. 91 Fludarabine 30 mg/m 2 /day for 4 days, cytarabine 1 g/m 2 /day for 4 days, and idarubicin 12 mg/m 2 /day for 3 days was successful in achieving engraftment in patients with myeloid leukemia and a matched sibling or one antigen-mismatched donor, although not in patients with unrelated donors. The regimen was developed to have some activity against the target malignancy, as well as providing immunosuppression; extended remission was observed in Ͼ50% of patients with CML 49 and chemotherapy-sensitive AML. 91 Khouri et al 50 (and subsequently others) reported the use of fludarabine 25-30 mg/m 2 /day for 4 to 5 days plus cyclophosphamide у1 g/m 2 /day for 2 days in patients with lymphoid malignancies; 50 this regimen was effective in achieving engraftment, and its use has been extended to a range of malignancies. 22, 84, 92 The combination of melphalan and fludarabine has also been studied. Giralt et al ) for the treatment of advanced acute leukemia; this somewhat more intensive regimen is sufficiently immunosuppressive to allow engraftment of unrelated or one HLA-disparate-related transplants.
Slavin and coworkers 51 reported use of a reduced-toxicity preparative regimen consisting of busulfan 8 mg/kg, fludarabine 180 mg/m 2 , and antithymocyte globulin. Although less intensive and less toxic than commonly used ablative preparative regimens, this regimen produces marked myelosuppression and has not been administered without hematopoietic transplantation.
Another innovative approach involves treatment with low-dose total body radiation (2 Gy) with or without fludarabine. This regimen is minimally myelosuppressive, but allows engraftment in a high fraction of patients; 93, 94 patients achieve initial mixed chimerism and subsequent graft-versus-malignancy effects 95 and remissions have been reported in patients with a range of hematologic malignancies. Other lower-dose or nonablative regimens have been proposed.
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Preliminary results with nonablative allogeneic transplants
Most studies of nonmyeloablative hematopoietic transplants have been performed in elderly or medically debilitated patients unable to tolerate an ablative preparative regimen. Shimoni et al 99 reported on 36 patients, age 55 to 75 years, with acute myeloid leukemia, myelodysplasia, or chronic myeloid leukemia treated with fludarabine, cytarabine, and idarubicin as described above, followed by allogeneic hematologic transplantation from an HLA-matched or one antigen-mismatched sibling donor. 99 Patients with residual or recurrent disease received additional DLI or a second nonablative transplant. Initial engraftment with donor-derived cells was seen in 91% of patients. Treatmentrelated mortality was 20%. Acute GVHD (grade 2-4) occurred in 32% of patients, and chronic GVHD occurred in 52%. Complete remission was achieved in 88%. Thirteen patients were alive in remission with a median follow-up of 11.5 months (range, 4-40 months). The projected survival of patients who were in remission or had Ͻ10% bonemarrow blasts at the time of transplant was 59% at 2 years. The outcome of patients with refractory leukemia at transplant was poor; Ͻ10% remained in remission at 1 year.
These data indicate that nonmyeloablative allogeneic transplants are feasible in elderly patients with acceptable toxicity and GVHD rates. Patients with AML in relapse are not good candidates for this approach because of rapid recurrence, presumably before GVL can effectively develop. Patients transplanted in a minimal disease state, however, have done as well as younger patients transplanted with a high-dose ablative regimen. Giralt et al 100 reported a study involving a somewhat more myelosuppressive regimen of melphalan (180 mg/m 2 ) and fludarabine (125 mg/m 2 ) for the treatment of advanced acute leukemia. Patients with refractory relapse have approximately 25% extended disease-free survival, and 56% of patients with chemotherapy-sensitive disease remained in continuous remission beyond 1 year. These data suggest that a more myelosuppressive regimen is necessary in patients with active AML to prevent early relapse and to allow development of GVL. These results are similar to those achieved with ablative preparative regimens in younger, but otherwise similar patients.
Indolent lymphoid malignancies have also been successfully treated using this strategy. Khouri et al 50 treated 15 patients with far advanced CLL or transformed lymphoma using a nonmyeloablative regimen of fludarabine/ cyclophosphamide or fludarabine, cytarabine, and cisplatin. All patients failed to respond or recurred after primary chemotherapy. Durable engraftment was seen in 11 patients, with 50% to 100% donor cells at 1 month posttransplant, typically converting to 100% over the next 2 months. Hematopoietic recovery was prompt and no nonhematologic toxicity у grade 2 occurred. All 11 patients with engraftment responded, and eight achieved complete remission. Maximal responses developed slowly, occurring gradually over a period of up to 1 year. Patients failing to engraft recovered endogenous hematopoiesis promptly and had no serious adverse effects. Extending these studies to low-grade lymphoma, 11 additional patients received fludarabine 25 mg/m 2 /day for 5 days with cyclophosphamide 1 g/m 2 on day 4 and 5, followed by allogeneic blood stem cell transplantation. This produced minimal toxicity and a median of 6 days of neutropenia. All patients achieved engraftment and complete remission with no treatmentrelated mortality. 101 These results compare favorably to high-dose cyclophosphamide/total body radiation regimens in which treatment-related mortality typically exceeds 30%. 72 Other small studies have had similar findings. 22, 84, 95 Allogeneic bone marrow transplantation is associated with a high risk of treatment-related mortality in multiple myeloma, up to 70% in some studies. 102, 103 Use of a nonablative preparative regimen may reduce this morbidity while still inducing a graft-versus-myeloma effect. Giralt et al explored a regimen of melphalan (140 mg/m 2 ) and fludarabine (30 mg/m 2 for 4 days). Seven of 13 patients with far advanced myeloma achieved complete remission. 104 This promising approach requires further study.
Indications for a nonmyeloablative preparative regimen
Nonablative regimens are only useful in malignancies susceptible to graft-versus-malignancy effects. Success also Bone Marrow Transplantation requires development of an effective GVL effect before the underlying disease can progress. As indicated, this approach has generally been unsuccessful in patients with active, aggressive malignancies such as refractory acute leukemias. 91 In these cases, the malignancy is not eradicated by the nonablative regimen, and the disease tends to recur rapidly, outpacing the generation of graft-versusmalignancy effects. Nonablative regimens may be useful, however, for consolidation of remission in AML patients at high risk for relapse. Indolent malignancies that are not immediately life-threatening appear to be the best candidates for this strategy; responses developing over several months can be effective in relatively stable patients with CML in chronic phase or low-grade lymphoid malignancies. Of note, complete responses may occur even in cases with extensive disease.
Considerations for management with nonablative regimens
The optimal intensity of the preparative regimen depends on several factors, including the disease status and aggressiveness of the patient's malignancy, immunocompetence of the recipient, and histocompatibility differences between the donor and recipient. Young patients without comorbidities tolerate high-dose ablative regimens reasonably well and it is unclear if the benefits of a reduced toxicity regimen will outweigh the lesser cytoreduction of the malignancy. We presently recommend nonablative regimens only in older or infirm patients with myeloid malignancies given the established benefit of ablative regimens in patients up to age 55 years. On the other hand, the role of high-dose therapy is less established in patients with indolent lymphoid malignancies, and the promising results with nonablative regimens justify further study in patients of all ages.
Immunocompromised patients, such as those with advanced CLL, require less intensive immunosuppressive therapy to achieve engraftment than a fully immunocompetent recipient. Nonablative regimens have generally been studied in patients with an HLA-identical sibling or one antigen-mismatched donor. Greater immunosuppression is required for engraftment of HLA-nonidentical or unrelated transplants. Nonablative regimens have not reliably produced durable engraftment with T cell-depleted transplants or in haploidentical recipients, settings in which graft rejection remains a major problem even with ablative preparative regimens.
Acute GVHD can occur with nonablative regimens, but has been found to be relatively mild and controllable. The optimal post-transplant immunosuppressive therapy is uncertain; the agents given to prevent GVHD may also inhibit GVL. Two randomized studies report lower relapse rates in patients with AML receiving low-dose rather than full-dose cyclosporine. 105, 106 A variety of post-transplant immunosuppressive regimens have been utilized with nonablative transplants, including full-dose tacrolimus and methotrexate, abbreviated courses of these agents, or the combination of cyclosporine and mycophenolate mofetil. 95 The indications for DLI after nonablative preparative regimens need to be clarified. DLI have been considered to convert mixed chimerism into complete chimerism or enhance graft-versus-malignancy effects in patients with residual or recurrent disease. DLI should be used cautiously because of the risk of inducing GVHD, particularly within the first 6 months post-transplant. Patients who engraft and have Ͼ50% donor cells within the T cell compartment tend to spontaneously move toward complete chimerism, and DLI are not required. Malignancies slowly respond to GVL effects and may gradually resolve over the first year. We reserve DLI for those patients who have residual disease that either progresses or does not continue to decrease in size during the first year post transplant.
Separation of graft-versus-malignancy from GVHD
Effective strategies to separate the beneficial effects of GVL from the adverse manifestations of GVHD are critical for the success of nonablative hematopoietic transplantation. A number of approaches have been studied (Table  2) . With donor lymphocyte infusions, there is a doseresponse effect with higher rates of both GVHD and antileukemia responses with increasing doses of T cells. 65, 107, 108 The incidence of GVHD appears to be reduced by administration of graded doses of T cells, starting with 0.3-1.0 × 10 7 T cells/kg rather than a large single infusion. 109 An alternative strategy is to infuse T cell subpopulations that can mediate GVL with a reduced potential for GVHD. Selective depletion of CD8 + cells from the allogeneic donor marrow transplant reduces the incidence of GVHD. 110 Donor lymphocyte infusions using CD8-depleted cells have also been effective to reinduce remission in CML patients with a low rate of GVHD. 111 GVHD is initiated by alloreactive T cells. A novel strategy to prevent GVHD is to induce anergy in the donor T cell population against recipient alloantigens. Guinan et al 112 reported the cocultivation of donor marrow with recipient cells in the presence of CTLA-4Ig, an agent that blocks co-stimulation via the B7-CD28 pathway. 112 In a preliminary study, this approach allowed engraftment with manageable GVHD in haploidentical transplants.
Another strategy is to transduce donor T cells with a suicide gene, such as Herpes simplex virus thymidine kinase, which confers sensitivity to ganciclovir treatment. The viral thymidine kinase phosphorylates ganciclovir into the toxic triphosphate form. If the patient develops GVHD after infusion of the transduced cells, it can be abrogated by ganciclovir treatment. This approach has been successful in pilot studies using thymidine kinase-transduced T cells for donor lymphocyte infusions 113 or combining the transduced lymphocytes with T cell-depleted marrow transplants. 114, 115 Ganciclovir treatment may also abrogate GVL effects. It is uncertain if this strategy will improve leukemia-free survival. The transduction procedure may also change the composition and immune reactivity of the cells; initial studies suggest that the transduced cells appear less alloreactive, requiring higher doses to produce both GVL and GVHD. 116 This approach requires further evaluation in animal models, as well as human clinical trials.
Ex vivo depletion of alloreactive T cells is another potential approach to separate GVL from GVHD. Alloreactive cells stimulated in a mixed lymphocyte culture can be depleted by treatment with an immunotoxin that targets activation antigens, such as the interleukin-2 receptor. [117] [118] [119] The remaining nonactivated cells have a reduced potential to produce GVHD, yet may retain reactivity against infectious organisms and possibly the malignancy. Human studies are needed to determine if this approach will reduce the incidence of GVHD and provide beneficial immune activity.
An ideal cellular therapy would consist of leukemia-specific effectors devoid of graft-versus-host activity. T cell clones or lines have been successfully used for the treatment of Epstein-Barr virus-related lymphoproliferative disease 120 and cytomegalovirus infections 121 occurring after allogeneic bone marrow transplantation. Falkenburg et al reported a single case of a patient with CML who responded to an infusion of T cell lines raised against the leukemia. 122 The technology for development of therapeutic T cell clones is demanding, and this approach is not sufficiently developed to allow for large-scale clinical trials. Alternatively, T cells reactive against overexpressed malignancy-related antigens could be selected, expanded and parenterally administered as adoptive cellular therapy. 31 Nonablative hematopoietic transplants may become a platform for administration of cellular immunotherapy. Transplantation of allogeneic CD34
+ stem cells could be combined with engineered malignancy or infection-specific effectors devoid of graft-versus-host activity.
Conclusion
Use of relatively nontoxic, nonmyeloablative preparative regimens allows engraftment and generation of graftversus-malignancy effects. This approach is potentially curative for susceptible malignancies. This strategy reduces the risks of treatment-related morbidity and allows the use of allotransplantation for older patients and those with comorbidities that preclude high-dose chemoradiotherapy. The indications for a nonmyeloablative vs high-dose ablative preparative regimen need to be defined in controlled clinical trials. Controlled trials are ultimately needed to define the relative efficacy of nonablative transplants vs alternative standard chemotherapy for hematologic malignancies and selected solid tumors. 
